Key facts
- iHeart Japan’s last known valuation is $73.1M (Sep 2025).
- It has raised $21.1M; the latest was Later Stage VC ($5.4M) in Sep 2025.
- Notable investors include Mitsubishi UFJ Capital, SBI Investment, J-Startup, Resona Capital, UntroD — 16 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 16 names
- ·Watchlist + deal alerts for iHeart Japan
- ·The full record, as it builds
Funding rounds
No funding rounds for iHeart Japan are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About iHeart Japan
Developer of a cardiac regenerative medicinal product created to release patients from waiting for heart transplantation and to make it accepted broadly. The company provides a product that utilizes cell differentiation induction technology to attach a cell sheet to the heart to create a vascular network with blood circulation to bring better therapeutic effects and also provides healthcare contract and consulting services, enabling physicians to restore cardiac function as well as other organs such as the liver.
- Sector
- Healthcare
- HQ
- Kyoto, Japan
- Founded
- 2013
- Employees
- 15
- Website
- iheartjapan.jp/
- Ownership
- Privately Held (backing)
iHeart Japan doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in iHeart Japan shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on iHeart Japan in its N-PORT filings yet. We sweep new filings monthly.